Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir plus rilpivirine (LATTE-2) in the United States and Spain
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir plus rilpivirine (LATTE-2) in the United States and Spain
复制标题
DOI：
10.1371/journal.pone.0190487
复制
发表时间：
2018-01-05
期刊：
影响因子：
3.7
通讯作者：
Murray, Miranda
中科院分区：
文献类型：
--
作者：
Kerrigan, Deanna;Mantsios, Andrea;Murray, Miranda
艾滋病毒携带者(PLHIV)坚持每日口服抗逆转录病毒疗法(ART)的挑战刺激了可注射长效(LA)方案的发展。在一项IIb期研究(Latte-2)中，我们对美国和西班牙的可注射LA方案的参与者和提供者进行了39次深入采访。探讨参与者和提供者对LA与口头艺术的态度和体验的访谈被录音、转录并使用主题内容分析进行分析。参与者描述了LA注射与每日服药相比的便利性和情感上的好处，例如将艾滋病毒泄露的可能性降至最低，并消除了“每天提醒艾滋病毒携带者”。供应商认识到了好处，但警告说，洛杉矶的候选人仍然需要坚持去诊所注射，并对正在进行的临床管理提出了问题。在PLHIV中，LA被视为比日常口腔艺术更可取的选择。需要对适当的候选人进行进一步研究，包括对不同环境中的妇女和“非追随者”群体进行研究。
Challenges with adherence to daily oral antiretroviral therapy (ART) among people living with HIV (PLHIV) have stimulated development of injectable long-acting (LA) regimens. We conducted 39 in-depth interviews with participants and providers in a Phase IIb study (LATTE-2) evaluating an injectable LA regimen in the U.S. and Spain. Interviews exploring participant and provider attitudes and experiences with LA versus oral ART were audiotaped, transcribed and analyzed using thematic content analysis. Participants described the convenience of LA injections versus daily pills and emotional benefits such as minimized potential for HIV disclosure and eliminating the "daily reminder of living with HIV." Providers recognized benefits but cautioned that LA candidates still need to adhere to clinic visits for injections and raised questions around ongoing clinical management. LA was seen as preferable to daily oral ART among PLHIV. Further research is needed regarding appropriate candidates, including with women and "non-adherent" populations across settings.